Summer Krain
This is a likely match — the affiliation was inferred from OpenAlex, ORCID, and web sources but has not been fully confirmed. Treat with appropriate caution.
Researcher
Graduate Student Researcher
Research Areas
Biography and Research Information
OverviewAI-generated summary
Summer Krain's research focuses on infectious complications and treatment utilization in patients with relapsed/refractory multiple myeloma. Her work investigates the real-world implications of specific therapies, such as teclistamab, in this patient population. Krain collaborates with researchers at the University of Arkansas for Medical Sciences, including Trilok Shrivastava, Maurizio Zangari, Frits van Rhee, and Asis Shrestha, on shared publications. Her most recent publication is from 2026, indicating recent activity in the field.
Metrics
- Publications: 1
Selected Publications
-
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)
Collaboration Network
Top Collaborators
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
- Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma.
Similar Researchers
Based on overlapping research topics